4D Molecular Therapeutics (FDMT) EBT Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,565.00 |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | 36.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.21 Mn |
| Mar 31, 2026 | 37.98 Mn |
| Dec 31, 2025 | 496.50 Mn |
| Sep 30, 2025 | 139.82 Mn |
| Jun 30, 2025 | 48.88 Mn |
| Mar 31, 2025 | -24.56 Mn |
| Dec 31, 2024 | -513.49 Mn |
| Sep 30, 2024 | -146.14 Mn |
| Jun 30, 2024 | -83.96 Mn |
| Mar 31, 2024 | -12.69 Mn |
| Dec 31, 2023 | 17.20 Mn |
| Sep 30, 2023 | 509,002.00 |
| Jun 30, 2023 | 460,883.00 |
| Mar 31, 2023 | -754,502.00 |
| Dec 31, 2022 | 2.51 Mn |
| Sep 30, 2022 | -351,291.00 |
| Jun 30, 2022 | -1.77 Mn |
| Mar 31, 2022 | -143,167.00 |
| Dec 31, 2021 | -2.93 Mn |
| Sep 30, 2021 | -152,182.00 |